Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania - Wikidata - awgldk - TriplyDB

Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania

Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania

http://www.wikidata.org/entity/Q34312118

about

Tuberculosis vaccines and prevention of infection Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7)Protection against tuberculosis in Eurasian wild boar vaccinated with heat-inactivated Mycobacterium bovis Auditory impairments in HIV-infected individuals in Tanzania Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901.Vaccine against tuberculosis: what's new?A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults Immunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis.Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis Current status of new tuberculosis vaccine in children.Greater preexisting interferon γ responses to mycobacterial antigens and lower bacillary load during HIV-associated tuberculosis.Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma.Immunity to TB and targets for immunotherapy.Preventive effects of Mycobacterium vaccae on HIV-associated tuberculosis: a systematic review.Rationale for combining immunotherapy with chemotherapy.Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB.

P2860

Q26782022-2608313E-EDC6-4133-9DA6-81DBF42EA9FE Q28299689-69607FAD-8345-41E6-A1D8-A8124FD53401 Q28740383-05EEFC51-F491-49F8-BAAE-F319808F9E5A Q30412987-D86103D9-0D0C-4FC9-8AE2-D8E4EFEF4FE8 Q33675370-4AFAA720-76AD-4FD2-98FB-D6AD2302D2A4 Q35101472-779DE337-D4D0-4A3F-B0F2-4626A4AA9828 Q35889153-2470236B-FE3F-4D68-B883-5B1FC78484A0 Q36229621-51A94AE8-B547-4977-A633-91174B6068D1 Q36457649-01EF36BA-13F3-4759-9262-8AD5624701D9 Q37130796-2177D14F-C74F-4507-A514-2FB86EC82C45 Q37247486-1AC43004-505A-437F-8E36-D1A0BDAEBDBF Q37694879-E7E8D775-A2D0-448C-8075-C19AEF1347D5 Q37984571-83D436AA-8538-43DE-B6A9-CD12B84F7720 Q38106752-6C5A7935-7B55-4037-B776-92B6E5BB2199 Q38389326-5CE7136E-B0AB-4515-B803-E6CB2B16A755 Q44736504-731AB540-3288-41F1-9C71-BD54BD9BF033

P2860

Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania

http://www.wikidata.org/entity/Q34312118

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Immunogenicity of a protective ...... a phase III study in Tanzania

@ast

Immunogenicity of a protective ...... a phase III study in Tanzania

@en

Immunogenicity of a protective ...... a phase III study in Tanzania

@nl

type

label

Immunogenicity of a protective ...... a phase III study in Tanzania

@ast

Immunogenicity of a protective ...... a phase III study in Tanzania

@en

Immunogenicity of a protective ...... a phase III study in Tanzania

@nl

prefLabel

Immunogenicity of a protective ...... a phase III study in Tanzania

@ast

Immunogenicity of a protective ...... a phase III study in Tanzania

@en

Immunogenicity of a protective ...... a phase III study in Tanzania

@nl

P1433

Q34312118-45AC3B2F-78CB-48D4-AFB0-040366C0D223

P1476

Q34312118-0AC2397E-81F1-4655-B63A-4D8945013DA8

P2093

Q34312118-015EF811-F6B7-4D8E-967B-46556100E007

Q34312118-16CE8315-B2BE-48AE-8DA4-888F306AE1DC

Q34312118-2C64776F-F426-45AF-BFF3-6159F0D7D0D3

Q34312118-35592846-DB9B-4826-B19A-433289087281

Q34312118-4628B7CF-DB84-4362-BFB2-1C4BDA485120

Q34312118-753467BA-51C0-4796-9662-C11DB86962B8

Q34312118-8033F862-9888-4B7B-A57F-5B24520CC8B5

Q34312118-8EE02590-A586-4313-B14C-C4A4B1FB98A4

Q34312118-EF804AFE-7A5D-455C-BBD9-EBD008E18D0E

P2860

Q34312118-060D35F0-FD8D-4024-8756-6EDA8CA9A2B8

Q34312118-0F387F31-ED67-45F7-A2AD-B60849BF53BD

Q34312118-1C9335C8-68A5-4C6C-A9B7-AA0E3C6C66C4

Q34312118-215FEA2F-76F4-4FFD-84AF-4F7EBA7A487E

Q34312118-21C44249-A076-4C01-994A-92E7F1C69EC0

Q34312118-2C435DB1-7E7C-487C-B005-F39053CC775D

Q34312118-3A071ACD-E1FD-40E1-BF97-9118B0569133

Q34312118-3A4BA2F5-C5E6-414F-8203-497FE85173BD

Q34312118-5609641E-93E5-4A7A-AB45-0BBA261A4DF5

Q34312118-5AD128BC-CE03-4B4B-AA96-46400A441CAD

P304

Q34312118-E53B8BF4-4181-4476-B4A5-5A1E5B2601A3

P31

Q34312118-BC3482DC-559A-42B7-BDF3-DEABB5089E6A

P356

Q34312118-0CD8A444-51A6-4A6B-B25B-836B09E8BC4E

P407

Q34312118-650BBB52-AEA1-46D5-AF3A-2978A77B96B6

P433

Q34312118-42F2449E-D9AC-444F-A83C-D2BF7AB5EBD6

P478

Q34312118-438A7B81-E13C-45E9-B3D4-3A8E5E9A050A

P50

Q34312118-C9CF9A5A-7E85-45E2-A6F3-6F32B15D3734

P577

Q34312118-D25B5152-CD0E-4515-BE66-CEAFFEE658DA

P5875

Q34312118-2FF673E1-46EE-4E8F-8B9C-F959596D3A1B

P698

Q34312118-6B299532-EDF0-4238-808B-E669E90471F3

P921

Q34312118-C1DF6291-0F84-44DF-BC28-C37B7CF7B165

P932

Q34312118-4B4A6156-9CBF-4AB2-8D31-D97F8039B93A

P356

J.VACCINE.2010.09.041

P1433

P1476

Immunogenicity of a protective ...... a phase III study in Tanzania

@en

P2093

C Fordham von Reyn

http://www.w3.org/2001/XMLSchema#string

Jenni M Vuola

http://www.w3.org/2001/XMLSchema#string

Kisali Pallangyo

http://www.w3.org/2001/XMLSchema#string

Lillian Mtei

http://www.w3.org/2001/XMLSchema#string

Mecky Matee

http://www.w3.org/2001/XMLSchema#string

Muhammad Bakari

http://www.w3.org/2001/XMLSchema#string

Richard Waddell

http://www.w3.org/2001/XMLSchema#string

Robert D Arbeit

http://www.w3.org/2001/XMLSchema#string

Timothy Lahey

http://www.w3.org/2001/XMLSchema#string

P2860

A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers

Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations.

Lymphocyte proliferation to mycobacterial antigens is detectable across a spectrum of HIV-associated tuberculosis.

HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine.

Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens.

HIV preferentially infects HIV-specific CD4+ T cells.

Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis.

Variation in protection by BCG: implications of and for heterologous immunity.

Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study.

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature.

P304

7652-7658

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2010.09.041

http://www.w3.org/2001/XMLSchema#string

P407

P433

48

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46577691

http://www.w3.org/2001/XMLSchema#string

P698

20875492

http://www.w3.org/2001/XMLSchema#string

P921

P932

2981786

http://www.w3.org/2001/XMLSchema#string